Assembly Biosciences (NASDAQ: ASMB)
Assembly Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Assembly Biosciences Company Info
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
News & Analysis
Why Assembly Biosciences Stock Crashed Today
The clinical-stage biotech had a big pipeline setback.
Here's Why Assembly Biosciences Stock Is Soaring Today
An enthusiastic price for a secondary share offering lifted spirits and the stock.
2 Promising Hepatitis B Drugs, 1 Clear Winner Among Investors
Arrowhead Pharmaceuticals and Assembly Biosciences headed into an important industry meeting with rising share prices. Only one left the meeting with momentum intact.
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
Here's Why Assembly Biosciences Jumped Again on Thursday
Investors digesting a late-breaking data drop pushed up the stock.
Here's Why Assembly Biosciences Stock Soared Today
The company reported promising updates for two important pipeline programs.
Will the Gut Microbiome Change Medicine? Wall Street Isn't Convinced.
The potential is significant. Unfortunately, so is the hype.
Here's Why Assembly Biosciences Is Slipping Today
Mid-stage clinical trial results weren't what some investors were looking for.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.